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Abstract 
 Background: Despite the effectiveness of pharmacotherapy for the treatment 
of schizophrenia, up to 60% continue to experience distressing symptoms such as 
hallucinations or delusions. Adjunctive cognitive behavioural therapy (CBT) is now 
recommended  in many countries. There has been some debate as to whether CBT is 
effective in reducing the symptoms of schizophrenia. Meta-analyses to date have 
shown varying results. The aim of this meta-analysis was to examine moderating 
effects of a) study/trial quality, b) comprehensiveness of the CBT intervention, c) 
manualized vs. non manualized treatments, d) control group, e) chronicity of 
presentations of schizophrenia, and f) format of treatment. Method: A systematic 
search of the literature was conducted in PsychInfo, Scopus, Embase and Medline to 
identify randomized controlled trials reporting on the impact of CBT on positive, 
negative, global psychopathology and total symptoms and a random-effects meta-
analysis was performed.  Results: 23 studies including 2,639 participants published 
between 1990 and 2015 were identified. Small and largely non-significant effect 
sizes were found at post-treatment for total symptoms (g=0.19), negative symptoms 
(g= 0.12) and global psychopathology (g=0.12),, with a significant but small effect 
size found for the reduction of positive symptoms (g=0.19). Moderators had little 
impact overall, with no consistent evidence of quality, comprehensiveness, 
manualisation, control group, stage of illness or format of treatment moderating 
effect size for any symptom type. The clinical implications for the use of CBT with 
this population are discussed. 
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Schizophrenia is a chronic psychotic disorder that is characterised by a 
heterogeneous range of positive and negative symptoms that cause a profound 
disruption in most, if not all aspects of daily life. The disorder has been described in 
the literature since 1911 and has evolved significantly over time. While the 
prevalence is low, schizophrenia accounts for a significant financial burden to 
society. The nature of the disorder, the costs to society and current theoretical and 
treatment approaches are described below. A meta-analysis of existing cognitive-
behavioural treatments for schizophrenia is then conducted, which aims to address 
some of the limitations of existing meta-analyses in this field.   
Definitions, diagnosis and clinical features 
Schizophrenia is a psychotic disorder that is characterized by the presence of 
delusions, hallucinations, disorganized speech, disorganized or catatonic behavior 
and negative symptoms (APA, 2013). These symptoms must cause a significant 
impact on functioning and must be present for at least 6 months to warrant diagnosis 
(APA, 2013). The 12-month prevalence of schizophrenia in Australia is estimated to 
be less than 1% (AIHW, 2005; AIHW, 2014) and is estimated to be approximately 
1% in the USA (Tarrier & Wykes 2004). The DSM-5 criteria for schizophrenia is 
outlined in Appendix A. 
 Schizophrenia typically has an onset in late adolescence or early adulthood 
for men and early to mid-adulthood for women, and tends to persist for the 
remainder of the lifespan (Riecher-Rossler & Hafner, 2000). The onset of 
schizophrenia is generally preceded by a period of time whereby the individual may 
experience, or others may notice, changes in sleep, cognition, perception, and altered 
communication with others (Yung & McGorry, 1996, Larson, Walker & Compton, 
2010). The course of schizophrenia is often changing, with periods of recovery or 
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remission followed by relapse (Harrow et al., 1997), however approximately one 
third of patients demonstrate a chronic and stable course with limited or no periods 
of remission (Ciompi, 1980).  
In the literature psychotic symptoms are often divided into ‘positive’ and 
‘negative’ symptoms.  Positive symptoms are symptoms that are present in addition, 
or above, normal functioning and include delusions, hallucinations, disorganized 
speech and disorganized behavior. Negative symptoms are described as an ‘absence’ 
or decline in normal functioning. Often the negative symptoms precede the onset of 
the positive symptoms (Hafner et al., (1994), however, it is the positive symptoms 
that often leads to the diagnosis of schizophrenia (Tsuang et al., 2000).  
Positive symptoms.  Delusions occur in 65% of individuals with 
schizophrenia (Breier & Berg, 1999) and are defined as false beliefs that are held 
despite lack of evidence (APA, 2013). Delusions can come in many forms and the 
most commonly occurring delusions in schizophrenia are outlined in Table 1. 
Persecutory delusions are the most common, and occur in approximately 93% of the 
schizophrenic population (AlFaraj et al., 2006). Hallucinations also occur frequently 
in individuals with schizophrenia with auditory hallucinations being the most 
common (75% of patients), followed by visual hallucinations (34% of patients) and 
somatic hallucinations (29% of patients) (Bauer et al., 2011). Tactile, olfactory, and 
gustatory hallucinations occur less often (1.3-6.6% of patients) (Bauer et al., 2011). 
 
Table 1 
Type and description of common delusions 
Delusion Description 
Persecutory  A belief that one is being harassed, or might be harmed 
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Jealousy A belief that an individual’s spouse or partner are being 
unfaithful 
Passivity/Control A belief that one or one’s will is being controlled by something 
or someone, or that they can control others’ will 
Thought insertion A belief that thoughts are being intentionally inserted into 
one’s mind 
Thought 
withdrawal 
A belief that thoughts are being intentionally being removed 
from one’s mind 
Thought 
broadcasting 
A belief that one’s thoughts can be seen, heard or understood 
by others without those thoughts being spoken 
Grandiose A belief that one is of extreme importance or have extreme 
power 
Reference A belief that gestures and words of others are directed at them 
Religious Misguided beliefs around one’s relationship with God, or that 
they have been given special powers by God, or that they are 
God. 
Somatic Beliefs that one has a physical condition, or erroneous beliefs 
about parts of one’s body. 
Erotomanic A belief that someone is romantically or sexually involved or 
in love with him/her 
Guilt or Sin A feeling of remorse or guilt that is unfounded 
 
Disorganized speech, also known as formal thought disorder occurs in 
approximately 65% of individuals with schizophrenia (AlFaraj et al., 2006). This 
involves a heterogeneous range of symptoms and can include derailment, 
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tangentiality, incoherence, illogicality, circumstantiality, pressured speech, 
distractible speech and clang associations (AlFaraj et al., 2006; Rule, 2005; Harvey 
et al., 1997). Descriptions and prevalence rates for these symptoms are outlined in 
Table 2. Disorganised behaviours that are seen in schizophrenia include bizarre 
clothing or appearance, bizarre social or sexual behaviour, bizarre aggressive or 
agitated behaviour, and bizarre repetitive or stereotyped behaviours (Andreason, 
1995). These behaviours are the most commonly observed symptom for general 
practitioners seeing first episode psychosis (O’Callaghan et al., 2006). 
 Negative symptoms.  The negative symptoms in schizophrenia are also 
heterogeneous. The most easily observed are the symptoms that could be termed as 
blunting of affect. This includes unchanging facial expression, decreased 
spontaneous movements, lack of gesturing, poor eye contact, and lack of vocal 
inflections. Other negative symptoms include poverty of speech (short responses and 
minimal elaborations when speaking) and poverty of speech content (lack or 
reduction of quality of speech), blocking (a sudden inability to complete a sentence, 
or recall what that sentence was), poor grooming and hygiene, displays of anhedonia, 
diminished want or need for social relationships and inattentiveness. Approximately 
57% of schizophrenia patients experience at least one negative symptom (Bobes et 
al., 2010). 
 
Table 2 
Type and description of positive formal thought disorder symptoms 
Symptom Description Prevalence of 
Symptom  
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Derailment jumping from one topic to another 
unrelated topic mid-sentence 
50% 
Tangentiality digressing from the topic of 
conversation 
55% 
Incoherence words that are strung together in 
ways that do not make logical sense 
22% 
Illogicality conclusions are formed or arrived at 
that do not make logical sense  
Not provided 
Circumstantiality a difficulty in separating relevant 
from irrelevant information when 
describing an event 
33% 
Pressured Speech speaking rapidly, motivated by an 
urgency that is not observable by 
others, and often hard to understand 
21% 
Distractible Speech a change in subject in response to a 
stimulus 
18% 
Clang Associations grouping words together based on 
sound, rather than meaning 
3% 
Note. All prevalence rates were obtained from Alfaraj et al, 2006 
 
 
Distress, Functioning and Comorbidity in Schizophrenia 
Schizophrenia has severe and long-lasting impacts on daily functioning, 
including impairment in ability to attend to household tasks or self-care, or interact 
in reciprocal relationships with others (Ursano et al, 2004). It is estimated that up to 
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10% of individuals with schizophrenia will complete suicide (Dickerson & Lehman, 
2011) and despite the low prevalence rate, schizophrenia accounts for 20 % of all 
psychiatric admissions (AIHW 2001). The economic burden of schizophrenia in 
Australia is significant, resulting in direct costs of $661 million and indirect costs of 
$722 million (SANE, 2002). Estimates of employment for those with schizophrenia 
are low (4-27%) when compared to the general population (90%) (Marwaha & 
Johnson, 2004). Comorbidity with other disorders is common in schizophrenia and 
the most commonly co-occurring disorders include mood, anxiety and related 
disorders, and substance use disorders (Volkow, 2009).  
Etiological/Risk factors 
Despite decades of research into the cause of schizophrenia, to date there is 
still no clear factors that are common to all experiences of the disease (Walker et al., 
2004). The most common theories on the cause or risk of development of 
schizophrenia include those related to genetics, prenatal and postnatal factors, 
structural and functional abnormalities of the brain, neurotransmitter models, and 
environmental models. These are outlined briefly below. 
Genetics.  Numerous studies now demonstrate the genetic link in 
schizophrenia. For example, in a review of twin, adoption and family studies, Cardno 
& Gottesman (2000) found that monozygotic twins had the highest concordance rate 
(25-50%), followed by dizygotic twins (10-15%) and the development of 
schizophrenia became more distant from first degree to second degree relatives, 
suggesting a highly genetic component to the disorder. Additionally, adoption 
studies often examine rates of schizophrenia amongst biological and non-biological 
families of adoptees with the illness and have found a higher incidence of 
schizophrenia amongst parents and offspring in the biological family of the adoptee 
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with the illness, compared to the parents and relatives that reared them (Tienari  et 
sl., 2003). In a multistage genome-wide association study 22 genomic regions were 
found to be linked to schizophrenia (Ripke et al., 2013). Despite the gains made in 
this field, there are several limitations to this research. For instance, there seems to 
be no evidence that genetic vulnerability is specific to schizophrenia. For instance, 
Potash et al. (2001) found that there is significant overlap between schizophrenia and 
bipolar illnesses and argue that the presentation will take the form of one illness or 
another depending on other risk factors that may be inherited or acquired. 
Additionally, research has not yet elucidated whether the genetic vulnerability exists 
for all those who suffer from schizophrenia, and therefore some cases could be due 
to environmental risk factors (Walker et al., 2004). Several gene expression and 
association studies are finding promising, but not conclusive results for links with 
some signaling pathway, genetic variations and polymorphisms and call for larger 
studies (Andrews & Fernandez-Enright, 2015; Bangel et al., 2015; Liu et al., 2015; 
Sery et al., 2015).  
Prenatal and postnatal factors.  Others have studied the environmental 
triggers that affect fetal development and there have been numerous studies that have 
linked obstetrical complications with the development of schizophrenia (Cannon et 
al., 2000, McNeil et al., 2000), however effect sizes tend to be small (for example, 
0.31; Cannon et al., 2002). The role of maternal infections such as flu epidemics 
(Brown et al., 2004), prenatal exposure to rubella (Brown et al, 2001), and season of 
birth (Giezendanner et al., 2013) have also been found to increase the risk 
development of schizophrenia, and support the ‘dual hit’ hypothesis (Möller, 
Swanpoel & Harvey, 2015). This hypothesis suggests that a combination of genetics 
and an early environmental or inflammatory stressor can prime a person to an ‘event’ 
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later in life (such as drug abuse) which leads to the development of schizophrenia 
(Möller, Swanpoel & Harvey, 2015).  Postnatal factors such as brain injury have 
been linked to the development of schizophrenia, however published literature on 
this theory is mixed (Molloy et al., 2011). Meta-analyses such as those by Molloy 
and colleagues (2011) find an increased risk of the development of schizophrenia 
following a traumatic brain injury (up to 60%), however the lack of prospective 
studies in this area limit firm conclusions (David & Prince, 2005). Large longitudinal 
studies will help to elucidate the role of prenatal and postnatal factors on the 
development of schizophrenia.  
Brain abnormality.  Imaging studies have revealed enlarged brain 
ventricles, a decrease in brain volume, and reductions in the size of the hippocampus 
and thalamus in individuals with schizophrenia compared to controls (Lawrie & 
Abukmeil, 1998; Schmajuk, 2001; Pearlson et al 1989). Additionally, morphological 
abnormalities in the left temporal lobe have been discovered compared with controls 
(Crowe, 1990). However, despite the numerous findings, none of these results have 
been found to be specific to schizophrenia, or found across all patients with 
schizophrenia; or could be a consequence of the disease (Walker et al., 2004). 
Studies at the cellular level have discovered reductions in neuron density as well as 
abnormalities in their structure and interconnections (Arnold, 1999). Because these 
cellular abnormalities seem so widespread (Walker, 1994), researchers propose that 
schizophrenia involves some form of malfunction of neural circuits (Benes, 2000). 
Neurotransmitter models.  One of the key neurotransmitters linked with 
schizophrenia is dopamine. The dopamine hypothesis postulates that schizophrenia 
results from the brain producing too much dopamine (Howes & Kapur, 2009). This 
hypothesis was developed on the discovery that drugs such as amphetamines, which 
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increase the amount of dopamine in the brain, can also induce symptoms of 
schizophrenia (Grace, 1991; Davis et al., 1991). The dopamine hypothesis was 
further strengthened by the discovery that patients with Parkinson’s disease taking L-
Dopa to raise their dopamine levels often developed symptoms similar to 
schizophrenia if their dose was too high. Post mortems (Kestler et al., 2001) have 
demonstrated an increased density of the neurotransmitter in the striatum of patients 
with schizophrenia, and positron emission tomography (PET) scans (Lindstrom et 
al., 1999) have found dopaminergic processes in various mental activities and 
treatments; further strengthening the dopamine hypothesis. A second 
neurotransmitter that has more recently been implicated in schizophrenia is 
glutamate, whereby the blockade of certain glutamate receptors results in the 
experience of negative symptoms and cognitive impairments (Goff & Coyle, 2001). 
Gamma-aminobutyric acid (GABA), serotonin, and noradrenaline have also been 
implicated in the development of schizophrenia (Carlsson et al., 2001) and thus 
further research is needed to ascertain the role of neurotransmitter systems in 
schizophrenia.  
 Environmental factors.  Trauma histories are common in those with 
schizophrenia, and Morgan and Fisher (2007) found that childhood trauma was a risk 
factor for the later development of psychosis. Stressful life events, such as being 
raised in institutional settings or dysfunctional home environments have also been 
found to predict the development of schizophrenia (Walker et al., 2004). Other 
environmental factors linked with increased likelihood of the development of 
schizophrenia include cannabis use (adjusted odds ratios 1.41-2.43, Minozzi et al., 
2010), growing up in cities (odds ratios 1.05-2.51, Krabbendam & van Os, 2005), or 
being part of a minority group (effect size 2.9, Cantor-Graae & Selton, 2005). Whilst 
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none of these factors alone have a definite causal effect in the development of 
schizophrenia, they may create vulnerability that when linked with other factors, 
such as genetics, may increase the likelihood of developing schizophrenia (Van Os, 
Kenis & Rutten, 2010). 
Treatments 
Pharmacological.  Antipsychotic medications are the most commonly 
prescribed pharmacology in the treatment of schizophrenia (McGorry, 2005) and are 
the first line treatment in this disorder. Two forms of anti-psychotics are currently 
used, the older group, called ‘typical’ anti-psychotics (i.e., chlorpromazine, 
haloperidol and thioridazine), and the newer group, are called ‘atypical’ anti-
psychotics (i.e., olanzapine, risperidone, clozapine, quetiapine and amisulpride). 
Typical antipsychotics demonstrate efficacy (McGorry et al., 2003), but often have 
more side-effects (Miyamoto et al., 2005), especially if used in higher doses. 
Atypical medications are now the preferred treatment option because of their 
superior tolerability, probable greater efficacy in relapse prevention, and reduced risk 
of tardive dyskinesia (Miyamoto et al., 2005). However, despite adequate dosing up 
to 60% of patients continue to see medication-resistant symptoms (Lindenmayer, 
2000), and it is well recognized that antipsychotic medications have a limited effect 
on negative symptoms (Pilling et al., 2002). Compliance with medications is also a 
problem with only about 40% of patients being compliant due to issues such as poor 
insight, negative attitude towards medication, substance use, and poor therapeutic 
alliance (Lacro et al., 2002). The efficacy of adjunct psychological treatments is 
therefore of high importance and is the focus of this thesis. 
Psychological Treatments.  Many clinical guidelines including The Royal 
Australian and New Zealand College of Psychiatrists (RANZCP), National Institute 
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for Clinical Excellent (NICE) and World Health Organisation (WHO) recommend 
cognitive behavioural therapy (CBT) as an adjunct treatment for individuals with a 
psychotic illness (Buchanan et al., 2010; Killackey et al., 2008; McGorry, 2005; 
McGorry et al., 2003; NICE, 2014). However, despite CBT being listed as a 
recommended adjunctive treatment less than a quarter of patients living with a 
psychotic illness actually receive this form of therapy (Morgan et al., 2011). CBT for 
psychotic symptoms is generally based on the cognitive-behavioural model of 
psychosis, which is outlined below.  
Morrison’s model of psychosis (Morrison, 2001).  Morrison’s model of 
psychosis (Figure 1) is heavily drawn from Clark’s cognitive model of panic disorder 
(Clark, 1986).  Morrison (2001) proposes that the intrusions seen in schizophrenia 
are normal and distress occurs when intrusions are misinterpreted as being 
dangerous. For example, a normal intrusive thought might be misinterpreted by an 
individual with schizophrenia as an outside force trying to insert thoughts into their 
mind. The beliefs, and subsequent distress, is maintained by selective attention, 
previous experiences (Raune et al., 2009), and safety behaviours such as avoiding 
going out, shouting at voices or drinking alcohol (Northard, Morrison & Wells, 
2008). Based on this model common components of CBT for psychosis include 
establishing a therapeutic alliance and collaborative formulation (Sivec & 
Montesano, 2012), psycho-education (Dudley et al., 2007), coping skill development 
(Tarrier, 2008), cognitive strategies to address delusions and hallucinations (Fowler 
et al., 1995), behavioural strategies to address both positive and negative symptoms 
(Sivec & Montesano, 2012), targeting comorbid affective states (Morrison et al., 
2004) and relapse prevention (Morrison et al., 2004). These components are detailed 
in Appendix B. 
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Figure 1. Morrison’s (2001) model of psychosis. 
 
 
 
Effectiveness of CBT for schizophrenia.  There are now a number of clinical 
studies that have explored the efficacy of CBT and other psychological therapies in 
the treatment of schizophrenia. As a result, several meta-analyses that pool these 
results have now been conducted. An overview of results from these  meta-analyses 
are indicated in Table 3 and demonstrate that effect sizes for CBT range from 0.04 to 
1.25 (Newton Howes & Wood, 2013; Pilling et al., 2002), demonstrating significant 
variability. All report that cognitive behavioural therapy (CBT) is beneficial (Kurtz 
& Richardson, 2012; Pfmmatter, Junghan & Brenner, 2006; Zimmermann et al., 
2005; Pilling et al., 2002; Wykes et al., 2008), though some have found that it is not 
significantly more beneficial than other psychosocial therapies (Jones et al., 2012). 
Other studies differed from each other in what symptoms or outcomes were treated 
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successfully with CBT, some finding successful improvements in outcomes for 
positive symptoms (Zimmermann et al., 2005; Pfmmatter et al., 2006), and others 
finding no results for positive symptoms, but beneficial effects for social cognition 
symptoms such as theory of mind and facial affect recognition (Kurtz & Richardson, 
2012).  
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Table 3  
Overview of current meta-analyses comparing CBT for Schizophrenia with control on measure of positive symptoms, negative 
symptoms, global symptoms and total symptoms 
Author k N Control Group Interventions Effect Size 
P                 N                GP             T 
Pilling et al. 
(2002) 
8  393  SC na na 1.25 na 
Zimmermann et 
al. (2005) 
14 1484 WL, TAU, problem solving, 
recreation and SPT   
0.37 
 
na na na 
Pfmmatter et al. 
(2006) 
17 - PE, ST  0.47 
 
na 0.45 na 
Wykes et al. 
(2007) 
34 - TAU  0.37 0.44 na na 
Kurtz & 19 692 Varied TAU, skills training 0.15  0.26 0.68 na 
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Richardson 
(2012) 
groups  
Reckor & Beck 
(2012) 
7 383 RC, problem solving, ST, 
BF, informal support 
na 
 
na na 0.91 
Jones et al. (2012) 20 - ST, PE, Family Therapy 0.67 0.25 na na 
Newton-Howes & 
Wood (2013) 
9 602 SC na 
 
na na 0.04 
Burns et al. 
(2014) 
16 639 BF, PE, TAU, ST, WL, ST, 
SC 
0.47 
 
na 0.52 na 
Jauhar et al. 
(2014) 
50 - TAU, WL 0.25 0.13 na 0.33 
Velthorst et al. 
(2015) 
35 2312 TAU, BF, PE, SC, WL, ST  na 
 
0.09 na na 
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Note. k=number of studies, N= number of participants, RC = Routine Care, ST supportive psychotherapy, BF befriending, SC standard care, WL 
wait list, TAU treatment as usual, SPT supportive psychotherapy. PE psychoeducation. CBT cognitive behavioural therapy. P= positive symptom 
measure, N= negative symptom measure, GP= general psychopathology measure, T= total symptoms measure;  na= not assessed. 
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Limitations of current literature 
Despite the numerous meta-analyses conducted to date there continues to be 
considerable variability in findings. This variability may be in part explained by the 
methodological short comings of previous meta-analyses in this field. One major 
problem with the literature in this field is that many important potential moderators 
of outcome have not previously been explored. One particularly important moderator 
of outcome may be study quality. Controlling for study quality is important in order 
to limit the reporting of biased treatment effects. To date, only two meta-analyses in 
the field have controlled for the quality of studies (Wykes et al., 2008; Velthorst et 
al., 2015). Velthorst found that higher study quality (typically found in more recent 
years) resulted in lower effect size (Velthorst et al., 2015). Similarly, Wykes et al. 
(2008) found studies with lower quality scores produced larger effect sizes, though 
they were cognizant that other factors also affected the trial results (Wykes et al., 
2008).  
 Secondly, the comprehensiveness of quality of the CBT intervention may 
also account for inconsistent findings. For example CONSORT guidelines (Shulz, 
Altman & Moher, 2010) state that there needs to be “precise details of the 
interventions intended for each group and how and when they were actually 
administered” as well as a “description of the different components of the 
interventions and, when applicable, description of the procedure for tailoring the 
interventions to individual participants”.  To date no meta-analyses have examined 
the components of the CBT interventions that were delivered and have not used this 
as a moderator in meta-analytic studies.   Therefore it is possible that studies that 
utilized or reported few components of an effective CBT treatment for schizophrenia 
would result in lower effect sizes than those who contained a more comprehensive 
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package. No studies to date have done this, and determining quality of interventions 
is difficult (Herbert & Bø, 2005), but it has been argued that the way the intervention 
has been delivered is a potential source of clinical heterogeneity (Herbert & Bø, 
2005).   
Thirdly, there are currently no meta-analyses that have examined the difference 
between manualised and non-manualised CBT treatments. This is problematic 
because manualised treatments have been found to out-perform non-manualised 
treatments in other psychological conditions including phobia and anxiety disorders 
in adults (Schulte et al., 1994; Stewart & Shambless, 2009; Sharpless & Barber, 
2009; Wilson, 1996). Therefore this may also be an important factor in the 
schizophrenia research.  
Fourthly, only one meta-analysis to date has looked at the stage of psychosis 
and its impact of the effectiveness of CBT. Zimmerman et al. (2005) found that CBT 
was more effective for patients in the acute or early phase of treatment than those 
with chronic psychosis (Zimmerman et al., 2005). However this meta-analysis is 
now quite outdated, performed over 10 years ago. More recent meta-analyses either 
use studies that do not examine these effects, or lump all studies in together, which 
may account for the variance in heterogeneity between studies.  
Additionally, many studies differ in the type of control used, with some using 
some sort of passive control, such as a wait list control or treatment as usual 
conditions (Dunn et al., 2012; Durham et al., 2003), whilst others used an active 
control, such as supportive counselling (Pinto et al., 2009) or psycho-education 
(Cather et al., 2005). To date, one meta-analysis has found that studies using ‘active’ 
controls resulted in larger effect sizes than studies using ‘passive’ controls (Kurtz & 
Richardson, 2012). However, again most meta-analyses in this field group all control 
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groups together introducing unnecessary ‘noise’ to the data.   
 Finally, treatment format, in terms of whether the treatment is delivered in an 
individual or group setting may also account for differences in outcomes across 
meta-analyses. Two meta-analyses investigated treatment format and how it impacts 
on the outcome of CBT on schizophrenia (Wykes et al., 2008; Velthorst et al., 2015). 
These studies reported inconsistent findings, with Velthorst et al. (2015) finding that 
individual treatment resulted in higher effect sizes for reducing negative symptoms 
(Velthorst et al., 2015) and Wykes finding no evidence of a difference between the 
different treatment formats on symptom reduction (Wykes et al., 2008). 
 Given the inconsistent results and limitations of the existing meta-analyses, it 
is difficult to ascertain the efficacy of CBT for schizophrenia and therefore it is not 
known what is clinically the most effective intervention for a clinical psychologist to 
provide with this population. The aim of this meta-analysis is to address the 
abovementioned limitations by conducting a meta-analysis that a) considers the 
quality of the included studies; b) considers the components that constitute the CBT 
intervention used and measure how comprehensive the CBT intervention is; c) 
investigates the differences between manualised and non-manualised treatments; d) 
clearly defines the control group in terms of active or passive; e) investigates 
differences of CBT on acute and chronic presentations of schizophrenia; and f) 
considers the format of treatment to determine if individual or group formats result 
in larger effect sizes.  
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Method 
Search strategy 
Journal articles were identified through searches of PsychINFO, Scopus, 
Embase and Medline databases and were searched from 1990 to June 2014. The 
search terms ‘schizophrenia’, or ‘psychosis’ were combined with ‘cognitive behav* 
therapy’, ‘treatment’ and ‘trial’. Studies that were not in English language were 
excluded at the search level. Relevant studies were also identified through references 
of originally identified articles and published reviews, including meta–analyses. 
Study flow is included in Figure 2.  
 
 
COGNITIVE BEHAVIOURAL THERAPY (CBT) FOR SCHIZOPHRENIA  
  
22 
 
 
 
Figure 2. Study Flow. CBT= cognitive behavioural therapy. RCT= randomized 
controlled trial. 
Inclusion criteria 
Studies were included if 1) they were randomised control trials (RCTs); 2) 
they compared the effect of some variant of CBT to a non-CBT 
psychotherapy/control; 3) they provided sufficient information on outcome measures 
to calculate effect sizes; 4) they were investigating the effect of CBT on psychotic 
symptoms; 5) they used a measure of either positive symptoms, negative symptoms 
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or global psychopathology; 6) they were conducted after 1990; and 7) the study 
included original data (i.e., not duplicate data).  
Data Collection and Synthesis 
Intention-to-treat (ITT) data were used where possible, however completer 
data was used when this was not possible (indicated in Table 4). Data was analysed 
using Comprehensive Meta-Analysis Version 2.2 (Comprehensive Meta-Analysis, 
2014).  Pooled effect sizes with 95% confidence intervals (CI) (Hedges g) were 
calculated using a random effects model weighted for sample size and were 
calculated for total symptoms (i.e., the BPRS), positive symptoms (i.e., the PANSS 
positive scale or SAPS), negative symptoms (i.e., the PANSS negative scale or 
SANS), and general psychopathology symptoms (i.e., the PANSS general 
psychopathology (gp) scale). Consistent with previous interpretations, an effect size 
of 0.2 is considered a small effect, 0.5 a moderate effect, and 0.8 a large effect 
(Cohen, 1988). Between-group effect sizes were calculated for each study according 
to the following formula: 
𝑋1−𝑋2
𝑆𝐷𝑝𝑜𝑜𝑙𝑒𝑑
, where X1 represents the post-treatment score for 
the CBT condition and X2 is the post-treatment score for the control group. The 
pooled standard deviation was derived using the formula 
√(𝑁1 −1) ×𝑆𝐷1
  2+ (𝑁2 −1) ×𝑆𝐷2
  2 
 𝑁1+ 𝑁2−2
. 
In this formula N1 represents the CBT group sample, and N2 the sample size for the 
control group. Likewise, SD1 and SD2 represent the standard deviations of the CBT 
group and control groups respectively. Cohen’s d was then converted to Hedge’s g 
by multiplying it with the correction J formula: 𝐽(𝑑𝑓) = 1 −  
3
4𝑑𝑓−1
 (Borenstein et 
al., 2011). 
Publication bias was examined using Begg and Maumdar’s rank correlation 
(Begg & Mazumdar, 1994), Egger’s test of the intercept (Egger et al., 1997), and 
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Duval & Tweedie’s trim and fill method (Duval & Tweedie, 2000). Heterogeneity 
was assessed using the Q test and I² statistics. An I2 result of 25% is traditionally 
considered low, 50% moderate and 75% high levels of heterogeneity (Borenstein et 
al., 2009; Higgins et al, 2003).  
Study moderators include 1) study quality; 2) CBT comprehensiveness; 3) 
manualised vs. non-manualised interventions; 4) stage of psychosis; 5) active vs. 
passive control, and 6) treatment format (individual vs. group). Study quality was 
assessed with the Clinical Trials Assessment Measure (CTAM; Tarrier & Wykes, 
2004), which provides a study quality metric out of 100 taking into consideration 6 
domains of the trial: sample size, recruitment, treatment allocation, assessment of 
outcome, control group, description of treatment and analysis. Higher scores on the 
CTAM indicate a higher quality study. The comprehensiveness of the CBT 
intervention was assessed with the CBT for psychosis comphrensiveness scale 
(CPCS), which was developed specifically for this study and contains a checklist of 
20 CBT components that are often included in treatments for schizophrenia (see 
Appendix C). Categorical variables were assessed by a Q-test based on analysis of 
variance (Borenstein et al., 2009) and continuous variables were assessed by 
univariate meta-regression analysis (Borenstein et al., 2009). 
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Results 
Description of Studies 
The initial search identified 926 articles. A flowchart of the screening process is 
shown in Figure 1.Three hundred and seventy two duplicates were removed, 
resulting in 544 studies. These were then screened based on the inclusion criteria, 
first by reading the abstract and then the full article if it was not clear if the 
inclusion/exclusion criteria were met. Five-hundred and twenty-four articles were 
excluded for not meeting inclusion/exclusion criteria, resulting in 23 studies with a 
total of 2,639 participants. The majority of studies (60%) were conducted in the UK 
and the total duration of CBT ranged from 4 months to 18 months. Information on 
the included studies is outlined in Table 4.
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Table 4.  
Characteristics of the studies included in meta-analysis  
Study Country N Control 
group 
Treatment 
stage 
Outcome 
measure 
CBTCS Use of 
treatment 
manual 
Format CTAM 
Barrowclough et al. 
(2006) 
UK 113 P Chronic PANSS 12 Y G 74 
Barrowclough et al. 
(2010) 
UK 327 A NS PANSS 13 Y I 87 
Bechdolf et al. 
(2005) 
Germany 88 A Early PANSS 12 N G 85 
Cather et al. (2005) US 30 A NS PANSS 9 N I 71 
Dunn et al. (2012) UK 273 P Early PANSS 10 Y I 88 
Durham et al. (2003) UK 43 P Chronic PANSS 10 N I 72 
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PSYRATS 
Granholm et al. 
(2013) 
US 79 A NS PANSS, 
SANS 
11 Y G 72 
Granholm et al. 
(2014) 
US 149 A NS PANSS, 
SANS 
10 Y G 81 
Gumley et al. (2003) UK 144 A NS PANSS 10 N I 69 
Haddock et al. 
(1999) 
UK 20 A Early  BPRS 12 Y I 58 
Haddock et al. 
(2009) 
UK 71 P NS PANSS 16 Y I 65 
Jackson et al. (2007) AUS 62 P Early BPRS, 
SANS 
11 Y I 81 
Kuipers et al. (1997) UK 60 A Chronic BPRS 12 Y I 68 
Kuipers et al. (2004) UK 59 P Early PANSS 6 N I 54 
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Lewis et al. (2002) UK 315 P Early PANSS 11 Y I 74 
Li et al. (2014) China 192 A NS PANSS 15 Y I 75 
Lincoln et al. (2012) Germany 80 P NS PANSS 15 Y  I 82 
Peters et al. (2010) UK 74 P NS PANSS 9 N I 68 
Pinto et al. (1999) Italy 41 A NS BPRS, 
SAPS, SANS 
10 N I 27 
Rector et al. (2012) Canada 42 P NS PANSS 15 N I 67 
Tarrier et al. (2004) UK 315 P Early PANSS 13 Y I 90 
Valmaggia et al. 
(2005) 
Netherlands 
and Belgium 
62 A NS PANSS 9 Y I 78 
Note. CBTCS= CBT component score. US= United States UK= United Kingdom. AUS= Australia. A= Active Control. P= Passive Control. NS= Not Stated.  
PANSS positive and negative syndrome scale, BPRS brief psychiatric rating scale, SAPS Scale for the Assessment of Positive Symptoms, SANS scale for the 
assessment of negative symptoms, CPRS comprehensive psychiatric rating scale, PSYRATS psychotic symptom rating scales, SCS schizophrenia change scale, 
BRIANS brief assessment of negative symptoms scale. Y= Yes. N= No. G= Group intervention. I= Individual Intervention.
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Data Synthesis 
Total Symptoms.  Between-group effect sizes on measures of total symptoms 
are available for 11/22 (50%) studies. As indicated in Table 5 there was a small (g = 
0.19) and non-significant between-group effect size between CBT and control 
conditions. These studies were found to be moderately heterogeneous (Q1=27.55, 
p=.00; I²=63.70). The forest plot (Figure 3) demonstrates that the majority of studies 
demonstrate a mean positive effect for CBT, though all studies cross the 0.00 effect 
line, showing they do not differ significantly from no effect.   
The pre-treatment to post-treatment effect size was not moderated by quality of 
treatment (Q1=1.18,  p=.27; low quality: g=0.53; 95% CI: -0.23-1.31; high quality: 
g=-0.01; 95% CI: -0.01-0.00), comprehensiveness of the CBT treatment (Q1=0.70, 
p=.40; low comprehensiveness: g=-0.05; 95% CI: -0.15-0.07; high 
comprehensiveness: g=0.65; 95% CI: -0.61-1.92), or treatment manualisation 
(Q1=0.00, p=.99; manualised: g=0.19; 95% CI: -0.05-0.43; non-manualised: g=-0.19; 
95% CI: -0.82-1.20). Additionally, the treatment effect size was also not moderated 
by stage of illness (Q1=0.22, p=.97; acute: g=0.17; 95% CI: -0.05-0.39; chronic: 
g=0.13; 95% CI: -0.24-0.49), the type of control group used (Q1=0.01, p=.90; active: 
g=0.11; 95% CI: -1.16-1.37; passive: g=0.19; 95% CI: -0.04-0.42), or the treatment 
format used (Q1=0.07, p=.79; group: g=0.25; 95% CI: -0.14-0.65; individual: 
g=0.19; 95% CI: -0.06-0.44). 
Positive Symptoms.  Between-group effect sizes on measures of positive 
symptoms are available for 20/22 (91%) studies. As indicated in Table 5 there was a 
small (g = 0.16) but significant between-group effect size between CBT and control 
conditions. These studies were found to be moderately heterogeneous (Q1=33.89, 
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p=.03; I²=38.04). The forest plot (Figure 4) indicates a more positive result for CBT 
on positive symptoms and less variability than total symptoms.  
The pre-treatment to post-treatment effect size was not moderated by quality of 
treatment (Q1=2.28, p=.13; low quality: g=0.62; 95% CI: -0.00-1.25; high quality: 
g=-0.00; 95% CI: -0.01-0.00), comprehensiveness (Q1=0.21, p=.65; low 
comprehensiveness: g=-0.01; 95% CI: -0.05-0.03; high comprehensiveness: g=0.26; 
95% CI: -0.22-0.74), or treatment manualisation (Q1=0.11, p=.74; manualised: 
g=0.16; 95% CI: 0.05-0.27; non-manualised: g=-0.11; 95% CI: -0.16-0.38). 
Additionally, the treatment effect size was also not moderated by stage of illness 
(Q1=6.02, p=.11; acute: g=-0.14; 95% CI: -0.55-0.27; chronic: g=0.02; 95% CI: -
0.31-0.35), the type of control group used (Q1=0.27, p=.60; active: g=0.08; 95% CI: 
-0.16-0.32; passive: g=0.15; 95% CI: 0.04-0.27),  or the type of treatment format 
used (Q1=1.39, p=.24; group: g=-0.04; 95% CI: -0.43-0.34; individual: g=0.20; 95% 
CI: 0.10-0.29). 
Negative Symptoms.  Between-group effect sizes on measures of negative 
symptoms are available for 20/22 (91%) studies. As indicated in Table 5 there was a 
small (g = 0.12) and non-significant between-group effect size between CBT and 
control conditions. These studies were found to be moderately heterogeneous 
(Q1=31.48, p=.03; I²=39.66). The forest plot (Figure 5) indicates large variability 
between studies, with a small overall positive result for CBT on negative symptoms.  
The pre-treatment to post-treatment effect size was moderated by quality of 
treatment (Q1=5.73, p=.01), with low quality studies (g=0.86; 95% CI: 0.24-1.49) 
resulting in higher effect sizes than high quality studies (g=-0.01; 95% CI: -0.02—
0.00). The pre-post treatment effect size was not moderated by comprehensiveness 
(Q1=1.19, p=.27; low comprehensiveness: g=0.02; 95% CI: -0.02-0.06; high 
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comprehensiveness: g=-0.17; 95% CI: -0.67-0.33) or treatment manualisation 
(Q1=0.10, p=.75; manualised: g=0.10; 95% CI: -0.07-0.27; non-manualised: g=-0.14; 
95% CI: -0.06-0.35). Additionally, the treatment effect size was also not moderated 
by stage of illness (Q1=1.72, p=.63; acute: g=-0.03; 95% CI: -0.43-0.38; chronic: 
g=0.06; 95% CI: -0.33-0.45),  or the type of control group used (Q1=1.32, p=.24; 
active: g=0.05; 95% CI: -0.09-0.19; passive: g=0.21; 95% CI: -0.03-0.21). Finally, 
treatment effect size was moderated by format of treatment (Q1=5.29, p=.02), with 
individual treatment (g=0.19; 95% CI: 0.04-1.34) outperforming group treatments 
(g=-0.10; 95% CI: -0.29-0.10). 
Measures of Global Symptomatology.  Finally, between-group effect sizes on 
measures of global symptoms are available for 18/22 (82%) studies. As indicated in 
Table 5 there was a small (g = 0.12) and non-significant between-group effect size 
between CBT and control conditions. These studies were found to be moderately 
heterogeneous (Q1=69.09, p=.00; I²=75.40). The forest plot (Figure 6) shows more 
studies with larger positive effect sizes, however due to the high degree of variability 
between studies, the overall effect is still small.  
The pre-treatment to post-treatment effect size was moderated by quality of 
treatment (Q1=8.22, p=.00), with low quality studies (g=0.97; 95% CI: 0.35-1.60) 
resulting in higher effect sizes than high quality studies (g=-0.01; 95% CI: -0.02—
0.00). The pre-post treatment effect size was not moderated by comprehensiveness 
(Q1=1.20, p=.27; low comprehensiveness: g=0.02; 95% CI: -0.02-0.07; high 
comprehensiveness: g=-0.23; 95% CI: -0.77-0.32) or treatment manualisation 
(Q1=0.23, p=.63; manualised: g=0.17; 95% CI: -0.05-0.39; non-manualised: g=-0.04; 
95% CI: -0.41-0.50). Treatment effect size was moderated by stage of illness 
(Q1=9.45, p=.02), chronic presentations (g=0.38; 95% CI: 0.06-0.71) showing higher 
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effect sizes than acute stages of illness (g=-0.69; 95% CI: -1.29—0.08) indicating 
that CBT may be more effective on global psychopathology symptoms of 
schizophrenia in chronic stages of the illness. However due to the small number of 
studies in this comparison these results should be interpreted with caution. Treatment 
effect size was also moderated by control group used (Q1=3.69, p=.05), with passive 
controls (g=0.28; 95% CI: 0.04-0.53) showing higher effect sizes than active 
controls (g=-0.15; 95% CI: -0.53-0.22). Finally, the treatment effect size was not 
moderated by the type of treatment format used (Q1=1.63, p=.20; group: g=-0.32; 
95% CI: -1.12-0.47; individual: g=0.21; 95% CI: 0.01-0.41). 
 
Table 5  
Post-treatment group contrast analysis details 
Measure Studies Effect size (g) p 
Value 
Q 
Statistic 
p Value I²  
 k (95% CI)     
Total 11 0.19 (-0.04-0.42) .09 27.55 0.00 63.69 
Positive 22 0.16 (0.05-0.28) .01 33.89 0.04 38.04 
Negative 20 0.12 (-0.01-0.24) .07 31.48 0.04 39.66 
Global 18 0.12 (-0.09-0.33) .26 69.09 0.00 75.40 
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Figure 3. Forest plot of studies in the meta-analysis of total symptoms. 
  
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Tarrier et al 2004a 1.157 0.305 0.093 0.559 1.754 3.793 0.000
Tarrier et al 2004b 0.103 0.276 0.076 -0.438 0.644 0.372 0.710
Tarrier et al 2004c 0.335 0.296 0.087 -0.245 0.914 1.132 0.258
Lewis et al 2002 0.144 0.140 0.020 -0.130 0.419 1.031 0.303
Pinto et al 1999 0.718 0.332 0.111 0.067 1.370 2.161 0.031
Haddock et al 1999 -0.572 0.440 0.194 -1.435 0.290 -1.301 0.193
Kuipers et al 1997 0.342 0.289 0.084 -0.225 0.908 1.183 0.237
Barrowclough et al 2010 -0.185 0.121 0.015 -0.422 0.051 -1.536 0.125
Dunn et al 2012 0.213 0.189 0.036 -0.158 0.583 1.125 0.260
Durham et al 2003 -0.312 0.301 0.091 -0.903 0.278 -1.036 0.300
Barrowclough et al 2006 0.252 0.201 0.040 -0.142 0.646 1.252 0.211
0.117 0.064 0.004 -0.008 0.242 1.830 0.067
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
COGNITIVE BEHAVIOURAL THERAPY (CBT) FOR SCHIZOPHRENIA  
  
34 
 
 
Figure 4. Forest plot of studies in the meta-analysis of positive symptoms. 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Lincoln et al 2012 0.411 0.224 0.050 -0.028 0.849 1.834 0.067
Gumley et al 2003 0.347 0.167 0.028 0.020 0.675 2.079 0.038
Li et al 2014 0.040 0.144 0.021 -0.241 0.322 0.281 0.779
Jackson et al 2008 0.049 0.271 0.074 -0.483 0.580 0.180 0.857
Bechdolf et al 2005 -0.796 0.231 0.053 -1.249 -0.344 -3.450 0.001
Cather et al 2005 0.046 0.368 0.135 -0.675 0.767 0.126 0.900
Valmaggia et al 2005 0.305 0.266 0.071 -0.217 0.827 1.144 0.252
Bechdolf et al 2004 0.023 0.212 0.045 -0.393 0.439 0.107 0.915
Lewis et al 2002 0.123 0.140 0.020 -0.152 0.397 0.876 0.381
Pinto et al 1999 0.615 0.330 0.109 -0.031 1.261 1.865 0.062
Barrowclough et al 2010 -0.006 0.120 0.015 -0.242 0.230 -0.049 0.961
Granholm et al 2013 0.107 0.261 0.068 -0.404 0.618 0.411 0.681
Granholm et al 2014 0.406 0.224 0.050 -0.032 0.845 1.817 0.069
Haddock et al 2009 0.164 0.186 0.035 -0.202 0.529 0.878 0.380
Kuipers et al 2004 0.161 0.274 0.075 -0.376 0.698 0.588 0.556
Rector et al 2003 0.341 0.218 0.047 -0.086 0.768 1.566 0.117
Peters et al 2010 0.336 0.269 0.072 -0.191 0.863 1.248 0.212
Durham et al 2003 -0.016 0.307 0.094 -0.618 0.586 -0.052 0.958
Barrowclough et al 2006 0.034 0.200 0.040 -0.359 0.426 0.168 0.866
0.118 0.047 0.002 0.027 0.210 2.528 0.011
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Figure 5. Forest plot of studies in the meta-analysis of negative symptoms.  
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Lincoln et al 2012 -0.104 0.222 0.049 -0.538 0.330 -0.470 0.639
Gumley et al 2003 0.349 0.167 0.028 0.022 0.676 2.090 0.037
Li et al 2014 0.246 0.144 0.021 -0.037 0.528 1.701 0.089
Jackson et al 2008 0.445 0.275 0.075 -0.093 0.983 1.622 0.105
Bechdolf et al 2005 -0.284 0.223 0.050 -0.721 0.154 -1.270 0.204
Cather et al 2005 0.009 0.368 0.135 -0.712 0.730 0.025 0.980
Valmaggia et al 2005 -0.363 0.267 0.071 -0.886 0.160 -1.360 0.174
Bechdolf et al 2004 -0.162 0.213 0.045 -0.579 0.255 -0.762 0.446
Tarrier et al 2004a 0.934 0.297 0.088 0.352 1.516 3.144 0.002
Tarrier et al 2004b -0.090 0.274 0.075 -0.626 0.446 -0.330 0.742
Tarrier et al 2004c 0.064 0.294 0.086 -0.512 0.639 0.216 0.829
Pinto et al 1999 0.335 0.324 0.105 -0.300 0.971 1.035 0.301
Barrowclough et al 2010 -0.089 0.121 0.015 -0.325 0.147 -0.738 0.461
Granholm et al 2013 0.042 0.261 0.068 -0.469 0.552 0.159 0.873
Granholm et al 2014 -0.135 0.222 0.049 -0.570 0.299 -0.611 0.541
Haddock et al 2009 0.387 0.188 0.035 0.018 0.755 2.058 0.040
Kuipers et al 2004 0.115 0.274 0.075 -0.421 0.651 0.420 0.674
Rector et al 2003 0.479 0.219 0.048 0.049 0.909 2.182 0.029
Peters et al 2010 0.273 0.268 0.072 -0.253 0.799 1.018 0.309
Barrowclough et al 2006 0.062 0.200 0.040 -0.331 0.454 0.307 0.759
0.108 0.048 0.002 0.014 0.202 2.241 0.025
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Figure 6. Forest plot of studies in the meta-analysis of global psychopathology.
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Lincoln et al 2012 0.391 0.224 0.050 -0.047 0.829 1.750 0.080
Gumley et al 2003 0.294 0.167 0.028 -0.033 0.620 1.762 0.078
Li et al 2014 0.108 0.144 0.021 -0.174 0.390 0.752 0.452
Bechdolf et al 2005 -1.005 0.236 0.056 -1.467 -0.542 -4.259 0.000
Valmaggia et al 2005 -0.130 0.265 0.070 -0.649 0.390 -0.490 0.624
Bechdolf et al 2004 -0.386 0.214 0.046 -0.806 0.034 -1.801 0.072
Tarrier et al 2004a 1.010 0.300 0.090 0.423 1.597 3.371 0.001
Tarrier et al 2004b 0.072 0.273 0.075 -0.464 0.608 0.262 0.794
Tarrier et al 2004c 0.375 0.296 0.088 -0.205 0.956 1.266 0.205
Pinto et al 1999 0.718 0.332 0.111 0.067 1.370 2.161 0.031
Haddock et al 1999 -0.572 0.440 0.194 -1.435 0.290 -1.301 0.193
Kuipers et al 1997 0.342 0.289 0.084 -0.225 0.908 1.183 0.237
Barrowclough et al 2010 -0.291 0.121 0.015 -0.528 -0.053 -2.401 0.016
Haddock et al 2009 0.145 0.186 0.035 -0.221 0.510 0.776 0.438
Kuipers et al 2004 -0.305 0.275 0.076 -0.844 0.234 -1.108 0.268
Rector et al 2003 0.616 0.221 0.049 0.182 1.050 2.784 0.005
Peters et al 2010 0.446 0.270 0.073 -0.084 0.975 1.648 0.099
Barrowclough et al 2006 0.401 0.202 0.041 0.004 0.797 1.981 0.048
0.072 0.051 0.003 -0.027 0.172 1.430 0.153
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Publication Bias.  Funnel plots of the studies in the four main analyses are shown in 
Figure 7 (total symptoms), Figure 8 (positive symptoms), Figure 9 (negative 
symptoms), and Figure 10 (global psychopathology); and results of the analyses are 
shown in Table 6. Begg and Mazundar’s test and Egger’s test was not significant for 
any of the four main analyses. The trim and fill method imputed 2 studies in the meta-
analysis of total symptoms, reducing the effect size from 0.19 to 0.05. For the meta-
analysis of positive symptoms, the trim and fill imputed eight studies, reducing the 
effect size from 0.13 to -0.13. No studies were imputed for negative symptoms, 
suggesting no missing studies. Two studies were imputed for meta-analysis of global 
psychopathology, adjusting the effect size from 0.12 to -0.17. 
Table 6 
Results of tests for publication bias in the analyses of total symptoms, positive 
symptoms, negative symptoms and global psychopathology 
   
 
Effect size (95% CI) 
Begg & 
Mazumdar’s 
test 
 
 
Egger’s test 
 k Unadjusted Trim and Fill 
adjusted 
t p t p 
Total 11 0.19 (-0.04-0.42) 0.05 (-0.20-0.31) 0.25 0.27 1.26 0.23 
Positive 22 0.12 (0.01-0.24) -0.01 (-0.13-0.10) 0.11 0.48 0.67 0.50 
Negative 20 0.11 (-0.01-0.24) 0.11 (-0.01-0.24) 0.08 0.58 0.49 0.67 
Global 18 0.12 (-0.08-0.33) 0.04 (-0.17-0.25) 0.13 0.45 0.97 0.35 
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Figure 7. Funnel plot of studies in the meta-analyses of total symptoms. 
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Figure 8. Funnel plot of studies in the meta-analyses of positive symptoms. 
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Figure 9. Funnel plot of studies in the meta-analyses of negative symptoms. 
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Figure 10. Funnel plot of studies in the meta-analyses of global psychopathology. 
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Discussion 
Several meta-analyses have examined the effect of CBT on symptoms of 
schizophrenia. However the results of these studies are mixed and are also plagued 
with methodological limitations. Therefore, it remains difficult to determine if CBT 
is effective in reducing symptoms of schizophrenia. The aim of this study was to 
address the methodological limitations of existing meta-analyses and quantify the 
effectiveness of CBT for schizophrenia using a meta-analytic approach. Important 
moderators were also examined including 1) study quality; 2) comprehensiveness of 
treatment components; 3) manualised vs. non-manualised approaches; 4) stage of 
illness; 5) type of control group used; and 6) treatment format. 
Twenty-two RCTs were identified that measured changes in total, positive, 
negative and global psychopathology symptoms in response to CBT. The results of 
this meta-analysis found effect sizes for all symptoms measured to be in the ‘small’ 
range, and only CBT for positive symptoms produced a significant result. This 
finding is consistent with some of the more recently conducted meta-analyses of 
other authors (e.g., Velthorst et al., 2015; Jauhar et al., 2014; Newton-Howes & 
Wood, 2013), who found CBT produced only small effect sizes in symptom 
reduction (0.04-0.33). 
When looking at the effect of study quality on outcome it was found that for 
negative symptoms and global psychopathology symptoms, the higher quality trials 
produced lower effect sizes. This replicates in part the finding of Wykes et al., 
(2008) and Velthorst et al., (2015), who found for all symptom types significant 
differences in effect sizes of lower versus higher quality studies using the same 
measure (CTAM). Wykes (2008) found that high CTAM studies produced effect 
sizes of between 0.08 and 0.22. Wykes (2008) however used a cutoff score of 65 to 
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differentiate between high and low studies, rather than a continuous variable as used 
in this analysis, which may account for the difference. There was no effect of study 
quality on total and positive symptoms.  
There is some discussion that the effects of CBT in clinical trials have 
declined linearly since their introduction (Johnsen & Friborg, 2015). In their meta-
analysis of CBT for the treatment of depression, Johnsen and Friborg (2015) found 
that measures from self-report, clinician rating and rates of remission declined 
steadily, with modern trials providing less symptom reduction than the seminal 
studies that was not due to study design, number of participants, or study samples. It 
was suggested that these findings may be due to the higher quality of trials now 
being executed (Wykes et al., 2008), adherence levels to treatment manuals (Shafran 
et al., 2009), and the placebo effect (Johnsen & Friborg, 2015). 
To understand whether the type of CBT interventions used impacted on its 
effectiveness, a checklist was developed in this study to measure how many of the 
common components important to CBT for psychosis were included in the identified 
studies. Analysis found that effect sizes were no different for studies that only 
reported using a few common components than studies that reported using most of 
the identified components. Velthorst et al. (2015) looked at whether the number of 
behavioural components used in treatment (low versus high) had an impact on effect 
size. They found that it did not explain the heterogeneity found between studies, but 
there was a trend effect indicating that a more behavioural approach was slightly 
more effective in treating negative symptoms than a cognitive approach (Velthorst et 
al., 2015). This stands to reason, as behavioural activation improves anhedonia and 
desire for social contact in depression, with large effect sizes (SMD= 0.74) found in 
a recent meta-analysis (Ekers et al., 2014). 
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There were also no differences between the effect sizes of studies that 
adhered to a manualised treatment program and those that used non-manualised 
treatment interventions. This is the first study to date that that investigated this 
moderator in a meta-analysis of the effect of CBT for schizophrenia. No studies to 
date have examined the difference between these two types of treatment approaches, 
though many use measures of treatment adherence, indicating the importance of 
treatment manuals and protocols to show evidence based practice and reliable results 
(Rollinson et al., 2007; Durham et al., 2003; Kuipers et al., 1997; Turkington & 
Kingdon, 2000). Some research has indicated that manualisation leads to less 
effective outcomes due to limiting therapist flexibility (Castonguay et al.,1996), 
though studies examining this have reported that using manualized treatments does 
not limit flexibility (Connolly Gibbins et al., 2003), and therefore manualized and 
non-manualised treatments should not demonstrate differences in effect.  
The stage of illness (e.g., acute vs. chronic) was also investigated as a 
potential treatment moderator. Overall there was no effect of the stage of the illness 
on total symptoms, positive or negative symptoms, though global psychopathology 
symptoms were alleviated more in chronic conditions. Only one other meta-analysis 
has explored the difference between stages of illness on outcome of CBT using a 
meta-analytic approach. Zimmerman et al (2005) found a non-significant trend in 
favour of CBT for those in an acute phase of illness. Mean weight effect sizes for the 
acute phase were moderate (g=0.57) and small to moderate in chronic phases 
(g=0.27), though the two way ANCOVA was non-significant. These results are 
tenuous due to the methodological rigor and number of studies included in analyses. 
Further studies should be completed to examine the different symptom profiles in 
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each stage of the illness, mapping with effective treatment components as mentioned 
above to determine the most clinically effective treatment program for the individual. 
There was little difference in effect sizes when comparing CBT to treatment 
as usual or another ‘passive’ control, and between CBT and a more active control, 
such as supportive therapy. This study did find that some of the heterogeneity 
between studies measuring global psychopathology symptoms may be attributed to 
control type, with studies employing a passive control (g = 0.28)  resulting in a larger 
effect size than those using an active control (g=-0.15). This is a similar finding to 
that of Burns et al. (2014) and Sarin et al. (2011), who found that type of control 
group used did not result in significantly different effect sizes. This is in contrast 
however to the findings of Kurtz and Richardson (2012) however, who found studies 
with active control conditions resulted in larger effect sizes (d = 1.05) than those 
utilizing passive control conditions (d = -0.29). 
Finally, it was found that individual treatment (g = 0.19) was superior to 
group intervention (g = -0.10) in the alleviation of negative symptoms of 
schizophrenia, but treatment format was not important for the alleviation of other 
symptom types (total, positive and general psychopathology). This result replicates 
the results of Velthorst et al. (2015) who found that individual treatments reduced 
negative symptoms significantly more than group treatments. This finding has also 
been found in other psychological conditions including social anxiety disorder 
(Hedman et al., 2013) and bulimia nervosa (Chen et al., 2003). Potentially, those 
who find social contact and connectedness difficult or uninteresting, such as those 
with schizophrenia will benefit from a more individualized and personalized 
approach. 
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Why isn’t CBT effective for symptom reduction in schizophrenia? 
Recent meta-analyses (e.g., Velthorst et al., 2015; Newton-Howes & Wood, 
2013) have now consistently shown that CBT for schizophrenia results in small 
treatment effects. This is a significant contrast to the successful use of CBT for other 
psychiatric conditions including panic disorder, social anxiety disorder, and 
depression (Westen & Morrison, 2001; Acarturk et al., 2009; Hans & Hiller, 2013). 
However, few authors to date have discussed potential reasons why CBT produces 
small treatment effects. There may be a number of reasons for the small effect size of 
CBT for schizophrenia compared with other psychological conditions.  
Firstly, one potential reason for this small effect size is that in contrast to 
conditions such as panic disorder, social anxiety disorder, and depression mentioned 
above, schizophrenia is characterized by low levels of insight (Amador & 
Kronengold, 2004) and it has been suggested that CBT may be more effective for 
those who hold less conviction about these delusions and beliefs (Brabban et al., 
2009).  Secondly, another consideration in the effectiveness of CBT for 
schizophrenia is the length of treatment. Clinical guidelines recommend a minimum 
of 16 sessions of CBT (NICE, 2014), which if delivered weekly would equate to 4 
months of treatment. The length of treatment within the selected studies in this 
analysis varied from 5 weeks to 12 months, however even studies with longer 
treatments, such as 12 months, did not result in better results. For example, the 
Barrowclough et al. (2010) study delivered CBT over a 12 month period, but the 
result was that CBT was not significantly superior to control, and did not result in a 
large effect size (Barrowclough et al., 2012). Recently, there have been promising 
results found by investigating intensive approaches to CBT for other psychological 
conditions (Ehlers et al., 2014; Teng et al., 2015; Knuts, 2015; Foa et al., 2005) and 
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this may be of benefit to individuals with schizophrenia who require consistent and 
regular support to complete practice tasks or behavioural experiments, or for those 
that lack in social skills that could benefit from regular practice and skills training. 
Further, it may work well to engage individuals in intensive treatment during a stable 
phase of their illness, rather than risk putting treatment on hold, or gains being lost, 
during an acute phase. 
Limitations 
The aim of this study was to investigate the specific effect of CBT on 
symptom severity measures (i.e., total symptom scores, positive symptoms, negative 
symptoms and general psychopathology scores). This limited the number of studies 
that could be included in the meta-analysis as many studies including measures of 
constructs other than symptom severity such as relapse, hospitalization, self-esteem, 
or violence. The effect of CBT on these other important constructs was not assessed 
in this study and could be considered a limitation of the study. In addition, the 
number of studies included in some of the moderator analyses were very small, and 
therefore the power to detect true relationships may be reduced and thus these results 
should be interpreted with caution. 
Further study/recommendations  
Overall, it is clear that the recommendations outlined by Pilling et al. (2002) 
10 years ago, which have been echoed more recently (Rector & Beck, 2012; 
Newton-Howes & Wood, 2013), are still relevant today, and that more studies 
examining which components of CBT work for which patient populations are 
needed. Firstly, it may be useful to look at dismantling studies in this field, which 
have not been conducted to date.  Dismantling studies have been useful to determine 
which components of CBT are most effective for anxiety disorders for both children 
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and adults (Ale et al, 2015; Bryant et al., 2003) and depression (Dimidjian et al., 
2006; Kennard et al., 2009). 
Secondly, it may also be useful to investigate the supports surrounding the 
individual being treated and to use any possible social support networks to help the 
client understand concepts, practice tasks between sessions, and work towards their 
goals more holistically. Several studies have now started to look at how CBT can 
enhance other areas of functioning with promising results, such as CBT and 
vocational readiness (Lysaker et al., 2009) psychosocial rehabilitation programs 
(Pfmatter et al., 2006),  or CBT on depression (Jones et al., 2012). This has been 
used successfully in other diagnostic groups including depression, bipolar disorder, 
substance use and anxiety (Minjoo et al., 2014; Zhong et al., 2015).  
Thirdly, while this study did not find a difference in effectiveness for CBT 
across acute and more chronic phases of illness, other studies have found such 
differences for certain stages (Zimmerman, 2005), and others have found CBT may 
be of more benefit in key transitional periods, such as shifts from hospital or 
institutions such as prison to community (Thornicroft & Susser, 2001). An additional 
limitation of this field is that the treatment stage is not clearly described for all 
included participants. There are an increasing number of studies now looking at 
intervention in the prodromal or early stages of the illness with promising outcomes 
(Matsumoto et al., 2013; van der Gaag, 2012), and thus more studies investigating 
the effect of CBT in all phases is needed.  
Fourthly, treatment modalities other than CBT also deserve investigation in 
the future as it is possible that CBT may not be the most effective treatment for this 
population. Currently, other therapies such as compliance therapy (Kemp et al., 
1998; O’Donnell et al., 2003), acceptance and commitment therapy (Bach & Hayes, 
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2002; Gaudiano & Herbert, 2006), and metacognitive training (Moritz et al., 2010; 
Moritz et al., 2011), show promise in reducing symptoms of schizophrenia but do not 
yet have a lot of research behind them. Further controlled trials are needed are 
needed investigating these newer therapies.  
Finally, meta-analyses examining outcomes other than symptom reduction is 
also warranted. Many mental health services are now interested, and set key 
performance indicators in, more broad measures of wellbeing such as quality of life 
(Pilling et al., 2002, Rector & Beck, 2012), medication compliance (Rector & Beck, 
2012; Newton-Howes & Wood, 2013), social skills (Pfmatter et al. 2006; Kurtz & 
Richardson; 2012) and benefits in other areas of community and psychosocial 
functioning (Kurtz & Richardson, 2012). Therefore investigating the pooled effect of 
CBT and other treatments on these outcomes is also important in the future.  
Conclusion 
This study examined the effectiveness of CBT on symptom reduction in 
schizophrenia, and found small and largely not significant effect sizes for various 
types of symptoms. When examining moderators, the quality of the trial did have 
some impact, with higher quality trials resulting in lower effect sizes for general 
psychopathology and negative symptoms. The number of comprehensiveness of the 
CBT offered did not alter the effect of the treatment. The use of a manualized 
treatment was not superior to those who used non-manualised treatment protocols. 
CBT was no more effective for acute presentations than chronic presentations of the 
illness, though there was a significant difference in favor of chronic stages for 
general psychopathology symptoms. The type of control group used only impacted 
the results for the reduction of general psychopathology symptoms, with smaller 
effect sizes found when implementing an active control. Finally, individual treatment 
COGNITIVE BEHAVIOURAL THERAPY (CBT) FOR SCHIZOPHRENIA  
  
50 
 
was only superior to group treatment modalities for the reduction of negative 
symptoms. In summary, effect sizes remain small, and moderating effects are 
inconsistent in determining effective use of CBT for schizophrenia. Though CBT has 
been recommended as a therapy of choice by peak bodies such as the National 
Institute of Health and Care Excellence (NICE) and the Royal Australian and New 
Zealand College of Psychiatrists (NICE, 2014; McGorry, 2005) CBT is not being 
widely used by mental health services (Wykes et al., 2008).  CBT however remains 
the most researched and the most evidence-based treatment for schizophrenia and 
psychosis.  More study into effective components of CBT and symptom specific 
areas of focus for CBT is recommended to determine the most effective use of CBT 
for this population. 
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Appendices 
Appendix A  
DSM 5 criteria for schizophrenia 
Table 1. 
DSM-5 criteria for schizophrenia 
A. Two (or more) of the following, each present for a significant portion of time 
during a 1 -month period (or less if successfully treated). At least one of these 
must be (1 ), (2), or (3): 
1. Delusions. 
2. Hallucinations. 
3. Disorganized speech (e.g., frequent derailment or incoherence). 
4. Grossly disorganized or catatonic behavior. 
5. Negative symptoms (i.e., diminished emotional expression or avolition). 
B. For a significant portion of the time since the onset of the disturbance, level of 
functioning in one or more major areas, such as work, interpersonal relations, or self-
care, is markedly below the level achieved prior to the onset (or when the onset is in 
childhood or adolescence, there is failure to achieve expected level of interpersonal, 
academic, or occupational functioning). 
C. Continuous signs of the disturbance persist for at least 6 months. This 6-month 
period must include at least 1 month of symptoms (or less if successfully treated) 
that meet Cri- terion A (i.e., active-phase symptoms) and may include periods of 
prodromal or residual symptoms. During these prodromal or residual periods, the 
signs of the disturbance may be manifested by only negative symptoms or by two or 
more symptoms listed in Criterion A present in an attenuated form (e.g., odd beliefs, 
unusual perceptual experiences). 
D. Schizoaffective disorder and depressive or bipolar disorder with psychotic 
features have been ruled out because either 1 ) no major depressive or manic 
episodes have occurred concurrently with the active-phase symptoms, or 2) if mood 
episodes have occurred during active-phase symptoms, they have been present for a 
minority of the total duration of the active and residual periods of the illness. 
E. The disturbance is not attributable to the physiological effects of a substance (e.g., 
a drug of abuse, a medication) or another medical condition. 
F. If there is a history of autism spectrum disorder or a communication 
disorder of child- hood onset, the additional diagnosis of schizophrenia is made 
only if prominent delusions or hallucinations, in addition to the other required 
symptoms of schizophrenia, are also present for at least 1 month (or less if 
successfully treated). 
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Appendix B 
Psychological interventions for psychosis 
1 Establishing a therapeutic alliance and collaborative formulation. 
The development of a strong alliance is paramount in this population, given 
individuals often have difficulties with paranoia and intrusive or commanding 
voices (Sivec & Montesano, 2012). It is understood that this relationship may take 
time (Rector & Beck, 2001), but it is important for individuals to feel they can 
discuss their symptoms without judgment or fear of hospitalization (Sivec & 
Montesano, 2012). This allows the therapist to get a good understanding of their 
current symptoms and concerns, and possible beliefs driving these (Fowler et al, 
1995). A normalizing rationale is also a key ingredient to CBT for psychosis 
(Fowler et al, 1995; Rector & Beck, 2001), helping the individual understand that 
their experiences are not uncommon and are also experienced by those without 
schizophrenia, such as those with sleep deprivation, loss or trauma (Sivec & 
Montesano, 2012). This will pave the way for psychoeducation. 
2 Psychoeducation 
The stress-vulnerability model (Zubin & Spring, 1979) is often used to 
describe symptom onset, using the individual’s experiences rather than didactic 
learning (Fowler et al, 1995). A study examining the techniques used in the study by 
Sensky and colleagues (2000) determined that those considered ‘responders’ to 
treatment were those who received sound psychoeducation, and a normalizing 
experience including self-disclosure from the therapist (Dudley et al, 2007). 
3 Coping Strategies 
 This is often a first step for individuals, either because trust needs to be built 
over time before beliefs are challenged cognitively or behaviourally, or because 
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individuals are very fixed in their beliefs and cannot entertain an alternative view 
(Tarrier, 2008). Most commonly this involves distraction of attention techniques, 
including listening to music, or increasing/changing activity (Sivec & 
Montesano,2012; Tarrier, 2008). 
4 Cognitive Strategies 
 Techniques are focused on the individual’s perceived problems and 
symptoms as part of a collaborative case formulation (Fowler et al, 1995). Common 
strategies include awareness training, attention switching, modifying beliefs and self-
statements and reattribution of experiences (Tarrier, 2008). Common themes of 
cognitions that are targeted include threat of harm, loss of control, isolation and 
perceived defectiveness or worthlessness (Close & Schuller, 2004). Most treatments 
include a focus on changing or altering delusional beliefs and beliefs about 
hallucinations (Fowler et al, 1995;Sivec & Montesano, 2012; Tarrier, 2008). 
Techniques to reattribute or shift thoughts or beliefs are common to all CBT 
methods, and include tallying evidence for and against, using pie charts to explore 
the likelihood of alternative beliefs, the continuum task and behavioural experiments 
(Morrison et al, 2004). 
5 Behavioural Strategies 
 Behavioural components of CBT for schizophrenia typically include 
behavioural activation to improve negative symtpoms (Tarrier, 2008), and 
behavioural experiments to reality test unhelpful cognitions (Sivec & Montesano, 
2012). Common experiments for people with schizophrenia run along themes such as 
a person’s ability to act against the wishes of voices, that if they show weakness or 
vulnerability they will be attacked by others, that other people hold beliefs about 
them, and use of public transport (Morrison et al, 2004). 
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6 Targeting comorbid affective states 
 Morrison and colleagues recommend that therapists approach other affective 
states as they would if the person did not have psychosis. That is, with a 
comprehensive collaborative case formulation, the therapist and individual agree on 
what difficulties to target together, and evidence-based CBT techniques for 
depression, anxiety disorders, personality disorders, or substance use disorders are 
utilized as they would for any other person experiencing those difficulties (Morrison 
et al, 2004). 
7 Relapse Prevention 
Relapse prevention often follows a typical course: identifying triggers and 
identifying strategies that can be utilized to target that stressor/trigger (Morrison et 
al, 2004). Many packages have been developed around this, including the Wellness 
Recovery Action Plan described by Mary Copeland (1997) which details the 
development of a wellness ‘toolbox’, giving the individual an understanding of what 
keeps them well, and what changes they notice when they become unwell. It then 
guides them through identifying daily maintenance for keeping well, triggers, early 
warning signs, when things are breaking down and a crisis plan, as well as post crisis 
planning. 
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Appendix C 
Checklist of important components of CBT for schizophrenia 
 Normalising Symptoms 
 Psychoeducation and engagement 
 Cognitive Component (restructuring or behavioural experiments) 
 Behavioural Component (exposure, behavioural activation) 
 Address positive and/or negative symptoms in treatment 
 Address other symptoms (anxiety/depression) 
 Homework assigned 
 Manualised/Structured 
 At least weekly sessions 
 Problem Solving Skills component 
 Social Skills component 
 Coping Skills component 
 Medication Adherence module 
 Repeated measure of symptoms (more than pre-post measures) 
 Relapse prevention component 
 CBT trained clinician delivering intervention 
 Therapist that is trained/experienced in treatment of psychosis 
 Supervision provided for therapists 
 Risk Management specified 
 
Score ___ (out of 20). 
